Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating